Sodium Bicarbonate Injection

[Pharmacology and Toxicology] ①. Treat metabolic acidosis. This product increases the concentration of carbonate in plasma and neutralizes hydrogen ions, thereby correcting acidosis; ②. Alkalinize urine. Since the pH value increases after the concentration of carbonate in urine increases, uric acid, sulfonamide drugs and hemoglobin are not easy to form crystals or aggregates in urine; ③. Acid antacid. Oral administration can quickly neutralize or buffer gastric acid without directly affecting gastric acid secretion. Therefore, the rapid increase in gastric pH relieves the symptoms caused by high gastric acid. [Pharmacokinetics] This product enters the blood circulation directly after intravenous infusion. Sodium bicarbonate in the blood is filtered by the glomerulus and excreted in the urine. Some bicarbonate ions combine with hydrogen ions in urine to form carbonic acid, which is then decomposed into carbon dioxide and water. The former can diffuse into renal tubular cells, combine with intracellular water to form carbonic acid, and the dissociated bicarbonate ions are reabsorbed into the blood circulation. The bicarbonate ions in the blood combine with hydrogen ions in the blood to form carbonic acid, which is then decomposed into carbon dioxide and water. The former is exhaled through the lungs.

The main ingredient of this product is: sodium bicarbonate.

This product is a colorless clear liquid.

(1) Treatment of chemical acidosis. For the treatment of mild to moderate chemical acidosis, oral administration is preferred. For severe chemical acidosis, intravenous drip should be used, such as in severe kidney disease, circulatory failure, cardiopulmonary resuscitation, extracorporeal circulation, severe primary lactic acidosis, diabetic ketoacidosis, etc. (2) Alkalization of urine. Used for the prevention of uric acid kidney stones, reducing the renal toxicity of sulfonamide drugs, and acute hemolysis to prevent hemoglobin deposition in the renal tubules. (3) As an antacid, it treats symptoms caused by excessive gastric acid. (4) Intravenous drip has a non-specific therapeutic effect on certain drug poisonings, such as poisoning by barbiturates, salicylates, and methanol. However, this product is contraindicated for gastric lavage in case of ingestion of strong acid poisoning, because this product reacts with strong acid to produce a large amount of carbon dioxide, which can lead to acute gastric dilatation or even gastric rupture.

Metabolic acidosis, intravenous drip, the required dose is calculated as follows: alkali supplement amount (mmol) = (-2.3-actually measured BE value) × 0.25 × body weight (kg), or alkali supplement amount (mmol) = normal CO2CP-actually measured CO2CP (mmol) × 0.25 × body weight (kg). Unless the body loses bicarbonate, generally give 1/3 to 1/2 of the calculated dose first, and drip it in 4 to 8 hours. During cardiopulmonary resuscitation, the first dose is 1mmol/kg, and the dosage is adjusted according to the results of blood gas analysis (each 1g of sodium bicarbonate is equivalent to 12mmol bicarbonate). The concentration range for intravenous application is 1.5% (isotonic) to 8.4%.

(1) When a large amount of injection is given, arrhythmia, muscle cramps, pain, abnormal fatigue and weakness may occur, mainly due to hypokalemia caused by metabolic alkalosis. (2) When the dose is too large or there is renal insufficiency, edema, mental symptoms, muscle pain or convulsions, slow breathing, bad taste in the mouth, abnormal fatigue and weakness may occur. Mainly caused by metabolic alkalosis. (3) Long-term use may cause frequent urination, urgent urination, persistent headache, loss of appetite, nausea and vomiting, abnormal fatigue and weakness, etc.

It is contraindicated for those who are allergic to this product.

Precautions for children: For the treatment of acidosis, refer to the adult dose. During cardiopulmonary resuscitation, the first intravenous injection is 1mmol/kg of body weight, and the dosage is adjusted according to the results of blood gas analysis. Precautions for pregnancy and lactation: 1. Long-term or large-scale use can cause metabolic alkalosis, and excessive sodium load can cause edema, etc. Pregnant women should use it with caution. 2. This product can be secreted through breast milk, but there is no relevant information on its effects on infants. Precautions for the elderly: This experiment has not been conducted and there are no reliable references.

(1) When used in combination with adrenocortical hormones (especially those with strong mineralocorticoid effects), adrenocorticotropic hormone, and androgens, hypernatremia and edema are likely to occur. (2) When used in combination with amphetamine and quinidine, the renal excretion of the latter two is reduced, and toxic effects are likely to occur. (3) When used in combination with anticoagulants such as warfarin and M cholinesterase drugs, the absorption of the latter is reduced. (4) When used in combination with calcium-containing drugs, milk and dairy products, milk-alkali syndrome may occur. (5) When used in combination with H2 receptor antagonists such as cimetidine and ranitidine, the absorption of the latter is reduced. (6) When used in combination with potassium-excreting diuretics, the risk of hypochloremic alkalosis is increased. (7) This product can alkalinize urine and affect the renal excretion of ephedrine, so the dose of ephedrine should be reduced when used in combination. (8) The increase in sodium load increases the renal excretion of lithium, so when used in combination with lithium preparations, the dosage of lithium preparations should be adjusted as appropriate. (9) Alkalinizing urine can inhibit the conversion of methenamine into formaldehyde, thereby inhibiting the latter's therapeutic effect, so the two drugs are not recommended to be used together. (10) This product can increase the excretion of salicylic acid preparations by the kidneys by alkalinizing urine.

Keep tightly closed.

250ml:12.5g

Wuhan Fuxing BIO- Pharmaceutical Co., Ltd.

• Founded in:

  2002-10-17

• Address:

  No. 9, Fuxing Road, Hanchuan Economic Development Zone, Hubei Province

• Tax NO.:

  91420984741439934X

• Registered Funds:

  100 million yuan

• Website:

  Log in to view

• Email:

  Log in to view